Celgene Corporation (NASDAQ:CELG)’s stock had its “outperform” rating restated by Credit Suisse in a research note issued on Thursday. They currently have a $225.00 price target on the stock, up from their previous price target of $210.00. Credit Suisse’s target price would suggest a potential upside of 31.23% from the company’s current price. Celgene Corporation (NASDAQ:CELG) stock performance was 0.88% in last session and finished the day at $172.92. Traded volume was 3.00million shares in the last session and the average volume of the stock remained 3.14million shares. The beta of the stock remained 1.12. Celgene Corporation (NASDAQ:CELG) insider ownership is 0.20%.

Omeros Corporation (NASDAQ:OMER) Director Peter A. Md Demopulos purchased 6,153 shares of the stock in a transaction dated Tuesday, June 24th. The shares were purchased at an average cost of $16.20 per share, for a total transaction of $99,678.60. Following the purchase, the director now directly owns 181,220 shares in the company, valued at approximately $2,935,764.Omeros Corporation (NASDAQ:OMER) rose 8.92 percent to $17.47 Wednesday on volume of 1.15million shares. The intra-day range of the stock was $16.20 to $17.72. Omeros Corporation (NASDAQ:OMER) has a market capitalization of $592.45million.

Repligen Corp. (NASDAQ:RGEN) Director Thomas F. Ryan, Jr. sold 10,000 shares of Repligen Corp. stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $21.78, for a total value of $217,800.00. Following the sale, the director now directly owns 50,312 shares in the company, valued at approximately $1,095,795. Repligen Corporation (NASDAQ:RGEN)’s stock on June 25, 2014 reported a increase of 0.46% to the closing price of $22.01. Its fifty two weeks range is $7.52 -$22.21. The total market capitalization recorded $705.20million. The overall volume in the last trading session was 358,014.00million shares. In its share capital, RGEN has 32.04million outstanding shares.

On June 6, 2014, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Pain Therapeutics, Inc. (NASDAQ:PTIE) approved changes in compensation for the Company’s named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission) with respect to the officers’ and the Company’s performance from mid-2013 to mid-2014. On Wednesday, shares of Pain Therapeutics, Inc. (NASDAQ:PTIE) advanced 3.00% to close the day at $5.84. Company return on investment (ROI) is 65.00% and its monthly performance is recorded as 18.46%. Pain Therapeutics, Inc. (NASDAQ:PTIE) quarterly revenue growth is 10.19%.